Skip to main content

Puma Biotechnology Inc (NYSE:PBYI) Investor Investigation Concerning Potential Violations Of Securities Laws Announced

  • If you purchased shares of Puma Biotechnology Inc (NYSE:PBYI), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Site Members can sign up for company wide alerts

Investigation Overview

December 5, 2014 (Update) - On July 22, 2014, Puma Biotechnology Inc announced positive top line results from the Phase III clinical trial of Puma's investigational breast cancer drug, PB272 (neratinib). Puma Biotechnology Inc said that based on the results from the ExteNET study, Puma plans to file for regulatory approval of neratinib in the extended adjuvant setting in the first hal...



You must register (for free) or login to view the entire investigation.